• 1
    Miller PE. The glaucomas. In: Slatter's Fundamentals of Veterinary Ophthalmology. (ed. Maggs DJ, Miller PE, Ofri R) Saunders Elsevier, St Louis, 2007; 230257.
  • 2
    Miller PE, Schmidt GM, Vainisi SJ et al. The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial. Journal of the American Animal Hospital Association 2000; 36: 431438.
  • 3
    Focht T, Bentley E, Miller PE. Can initial response to latanoprost therapy be used as a prognostic indicator in canine patients with primary closed angle glaucoma? 37th Annual Meeting of the American College of Veterinary Ophthalmologists; November 2, 2006, San Antonio, TX: American College of Veterinary Ophthalmologists; 2006. p. 48.
  • 4
    Bentley E, Miller PE, Murphy CJ et al. Combined cycloablation and gonioimplantation for treatment of glaucoma in dogs: 18 cases (1992–1998). Journal of the American Veterinary Medical Association 1999; 215: 14691472.
  • 5
    Sapienza JS, van der Woerdt A. Combined transscleral diode laser cyclophotocoagulation and Ahmed gonioimplantation in dogs with primary glaucoma: 51 cases (1996–2004). Veterinary Ophthalmology 2005; 8: 121127.
  • 6
    Gelatt KN. The canine glaucomas. In: Veterinary Ophthalmology, 2nd edn. (ed. Gelatt KN) Lea and Febiger, Philadelphia, 1991; 396428.
  • 7
    Gelatt KN, MacKay EO. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Veterinary Ophthalmology 2001; 4: 283288.
  • 8
    Marsh BC, Cantor LB. The Spaeth Gonioscopic Grading System. Glaucoma Today 2005; 2225.
  • 9
    Tsai S, Miller PE, Struble C et al. Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs. Veterinary Ophthalmology 2012; 15(Suppl 1): 7178.
  • 10
    Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Survey of Ophthalmology 2008; 53(Suppl 1): S107S120.
  • 11
    Ward DA. Effects of latanoprost on aqueous humor flow rate in normal dogs. 36th Annual Meeting of the American College of Veterinary Ophthalmologists; October 12–15, 2005; Nashville, TN2005. p. 15.
  • 12
    Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: the Proctor Lecture. Investigative Ophthalmology & Visual Science 2001; 42: 11261133.
  • 13
    Dinslage S, Diestelhorst M, Kuhner H et al. [The effect of latanoprost 0.005% on pupillary reaction of the human eye]. Ophthalmologe 2000; 97: 396401.
  • 14
    Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Investigative Ophthalmology & Visual Science 1995; 36: 24612465.
  • 15
    Yamaji K, Yoshitomi T, Ishikawa H et al. Prostaglandins E1 and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction. Current Eye Research 2005; 30: 661665.
  • 16
    Troiano P, Oldani A, Gozzini C et al. Latanoprost 0.005%: evaluation of its effect on accommodative capacity. Acta Ophthalmologica Scandinavica. Supplement 2000; 232: 5254.
  • 17
    Kurtz S, Leibovitch I, Shemesh G et al. The effect of latanoprost on accommodation in young patients with ocular hypertension. Journal of Glaucoma 2003; 12: 5456.
  • 18
    Yoshitomi T, Ito Y. Effects of indomethacin and prostaglandins on the dog iris sphincter and dilator muscles. Investigative Ophthalmology & Visual Science 1988; 29: 127132.
  • 19
    Rohen JW, Kaufman PL, Eichhorn M et al. Functional morphology of accommodation in the raccoon. Experimental Eye Research 1989; 48: 523527.
  • 20
    Carreras FJ, Porcel D, Gonzalez-Caballero F. Expanding forces in aqueous outflow pathways of a nonaccommodating mammal: an approach via comparative dynamic morphology. Comparative Biochemistry and Physiology Part A, Physiology 1997; 117: 197209.
  • 21
    Abramson DH, Chang S, Coleman J. Pilocarpine therapy in glaucoma: effects on anterior chamber depth and lens thickness in patients receiving long-term therapy. Archives of Ophthalmology 1976; 94: 914918.
  • 22
    Van Alphen GW, Robinette SL, Macri FJ. Drug effects on ciliary muscle and choroid preparations in vitro. Archives of Ophthalmology 1962; 68: 8193.
  • 23
    Yang CC, Chou SC, Hung PT et al. Anterior chamber angles shallowing and intraocular pressure after topical pilocarpine. Journal of Ocular Pharmacology and Therapeutics 1997; 13: 219224.
  • 24
    Sarchahi AA, Abbasi N, Gholipour MA. Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs. Veterinary Ophthalmology 2012; 15(Suppl 1): 6470.
  • 25
    Gwin RM, Gelatt KN, Gum GG et al. The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous beagle. Investigative Ophthalmology & Visual Science 1977; 16: 11431148.
  • 26
    Almazan A, Tsai S, Miller PE et al. Iridocorneal angle measurements in mammalian species: normative data by optical coherence tomography. Veterinary Ophthalmology 2012; DOI: 10.1111/j.1463-5224.2012.01030.x.
  • 27
    Tsai S, Bentley E, Miller PE et al. Gender differences in iridocorneal angle morphology: a potential explanation for the female predisposition to primary angle closure glaucoma in dogs. Veterinary Ophthalmology 2012; 15(Suppl 1): 6063.
  • 28
    Slater MR, Erb HN. Effects of risk factors and prophylactic treatment on primary glaucoma in the dog. Journal of the American Veterinary Medical Association 1986; 188: 10281030.